5OC8

HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.56 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.237 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Jeay, S.Ferretti, S.Holzer, P.Fuchs, J.Chapeau, E.A.Wartmann, M.Sterker, D.Romanet, V.Murakami, M.Kerr, G.Durand, E.Y.Gaulis, S.Cortes-Cros, M.Ruetz, S.Stachyra, T.M.Kallen, J.Furet, P.Wurthner, J.Guerreiro, N.Halilovic, E.Jullion, A.Kauffmann, A.Kuriakose, E.Wiesmann, M.Jensen, M.R.Hofmann, F.Sellers, W.R.

(2018) Cancer Res. 78: 6257-6267

  • DOI: 10.1158/0008-5472.CAN-18-0338

  • PubMed Abstract: 
  • Activation of p53 by inhibitors of the p53-MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, and selective inhibitor of the p53-MDM2 interaction HDM20 ...

    Activation of p53 by inhibitors of the p53-MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, and selective inhibitor of the p53-MDM2 interaction HDM201 elicits therapeutic efficacy when applied at various doses and schedules. Continuous exposure of HDM201 led to induction of p21 and delayed accumulation of apoptotic cells. By comparison, high-dose pulses of HDM201 were associated with marked induction of PUMA and a rapid onset of apoptosis. shRNA screens identified PUMA as a mediator of the p53 response specifically in the pulsed regimen. Consistent with this, the single high-dose HDM201 regimen resulted in rapid and marked induction of PUMA expression and apoptosis together with downregulation of Bcl-xL in vivo Knockdown of Bcl-xL was identified as the top sensitizer to HDM201 in vitro , and Bcl-xL was enriched in relapsing tumors from mice treated with intermittent high doses of HDM201. These findings define a regimen-dependent mechanism by which disruption of MDM2-p53 elicits therapeutic efficacy when given with infrequent dosing. In an ongoing HDM201 trial, the observed exposure-response relationship indicates that the molecular mechanism elicited by pulse dosing is likely reproducible in patients. These data support the clinical comparison of daily and intermittent regimens of p53-MDM2 inhibitors. Significance: Pulsed high doses versus sustained low doses of the p53-MDM2 inhibitor HDM201 elicit a proapoptotic response from wild-type p53 cancer cells, offering guidance to current clinical trials with this and other drugs that exploit the activity of p53. Cancer Res; 78(21); 6257-67. ©2018 AACR .


    Organizational Affiliation

    Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.,Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland. stephane.ferretti@novartis.com francesco.hofmann@novartis.com.,PK Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland.,Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland.,Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.,Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.,Oncology Global Development, Basel, Switzerland.,Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.,Translational Clinical Oncology, Novartis Institutes for BioMedical Research, East Hanover, New Jersey.,Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
E3 ubiquitin-protein ligase Mdm2
A
96Homo sapiensMutation(s): 0 
Gene Names: MDM2
EC: 2.3.2.27
Find proteins for Q00987 (Homo sapiens)
Go to Gene View: MDM2
Go to UniProtKB:  Q00987
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CL
Query on CL

Download SDF File 
Download CCD File 
A
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
 Ligand Interaction
9QW
Query on 9QW

Download SDF File 
Download CCD File 
A
(4~{S})-5-(5-chloranyl-1-methyl-2-oxidanylidene-pyridin-3-yl)-4-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one
C26 H24 Cl2 N6 O4
AGBSXNCBIWWLHD-FQEVSTJZSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.56 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.237 
  • Space Group: P 61 2 2
Unit Cell:
Length (Å)Angle (°)
a = 56.406α = 90.00
b = 56.406β = 90.00
c = 104.913γ = 120.00
Software Package:
Software NamePurpose
PHASERphasing
PDB_EXTRACTdata extraction
REFMACrefinement
XDSdata reduction
XSCALEdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-06-29 
  • Released Date: 2018-08-22 
  • Deposition Author(s): Kallen, J.

Revision History 

  • Version 1.0: 2018-08-22
    Type: Initial release
  • Version 1.1: 2018-09-05
    Type: Data collection, Database references
  • Version 1.2: 2018-11-14
    Type: Data collection, Database references